Researchers from the University of Gothenburg, in collaboration with colleagues from University of Glasgow, present data that the drug Entresto (sacubitril/valsartan) which is commonly used for the treatment of cardiac failure leads to a marked reduction in plasma Aβ ratio, a candidate blood test for Alzheimer’s disease (AD).
Pharmalittle: PBMs are targeted in yet another congressional bill; access to new Alzheimer’s drug may not happen quickly
Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear
June 15, 2023